{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:32:15Z","timestamp":1793291535691,"version":"4.5.0"},"reference-count":98,"publisher":"Wiley","issue":"s89","license":[{"start":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T00:00:00Z","timestamp":1226361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:p>Histamine is a key mediator in the development of allergy symptoms, and oral H<jats:sub>1<\/jats:sub>\u2010antihistamines are among the most widely used treatments for symptomatic relief in conditions such as allergic rhinitis and chronic urticaria. Ebastine is a second\u2010generation antihistamine which has been shown to be an effective treatment for both seasonal and perennial allergic rhinitis. In controlled clinical trials in adult and adolescent patients with allergic rhinitis, ebastine 10\u2003mg once\u2010daily improved symptoms to a significantly greater extent than placebo and to a similar extent as loratadine 10\u2003mg and cetirizine 10\u2003mg (both once\u2010daily), while ebastine 20\u2003mg proved to be more effective than these two comparator antihistamines. In addition, ebastine was significantly more effective than placebo at relieving the symptoms of chronic idiopathic urticaria. Ebastine provides efficacy throughout the 24\u2010h dosing interval with once\u2010daily administration and clinical benefit is seen from the first day of treatment. Small studies have found beneficial effects for ebastine in patients with other disorders, including cold urticaria, dermographic urticaria, atopic asthma, mosquito bites and (in combination with pseudoephedrine) the common cold. In addition to the regular ebastine tablet, a fast\u2010dissolving tablet (FDT) formulation, which disintegrates in the mouth without the aid of a drink, is also available. It has been shown to be bioequivalent to the regular tablet, and to be significantly more effective than desloratadine at reducing histamine\u2010induced cutaneous wheals. A number of patient surveys demonstrated that the majority of individuals who tried the fast\u2010dissolving formulation reported it to be convenient for use, fast\u2010acting and preferred it to their previous antihistamine medication. Perhaps most importantly, a large proportion of patients indicated that they would prefer to use this new formulation in the future. Ebastine has a rapid onset of action and it can be administered once\u2010daily, with or without food. Dose modifications are not needed in elderly patients, or in those with renal or mild to moderate hepatic impairment. Ebastine is generally well\u2010tolerated, and clinical studies showed that at usual therapeutic doses of 10 and 20\u2003mg once\u2010daily, it had no clinically relevant adverse effects on cognitive function and psychomotor performance or on cardiovascular function. In conclusion, ebastine is an effective and generally well\u2010tolerated treatment for allergic rhinitis and chronic idiopathic urticaria. In addition to the regular tablet formulation, ebastine is available as a FDT, providing a treatment option that is particularly convenient for patients.<\/jats:p>","DOI":"10.1111\/j.1398-9995.2008.01897.x","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T10:25:35Z","timestamp":1226399135000},"page":"1-20","source":"Crossref","is-referenced-by-count":51,"title":["Ebastine in allergic rhinitis and chronic idiopathic urticaria"],"prefix":"10.1111","volume":"63","author":[{"given":"J.","family":"Sastre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,11]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2002.23625.x"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125003053"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2007.28.2934"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2003.00054.x"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00962.x"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059040-00018"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.8.1807"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118891"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.115569"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00013904"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02733.x"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00130832-200306000-00002"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00820.x"},{"key":"e_1_2_12_15_2","first-page":"277","article-title":"Medico\u2010economic aspects of the management of perennial allergic rhinitis in general medicine","volume":"30","author":"Dessi P","year":"1998","journal-title":"Allerg Immunol (Paris)"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00964.x"},{"key":"e_1_2_12_17_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2340\/00015555-0240","article-title":"Urticaria: current opinions about etiology, diagnosis and therapy","volume":"87","author":"Zuberbier T","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00130832-200310000-00008"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2007.28.2977"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.57.s75.2.x"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00526.x"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb05288.x"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP39126"},{"key":"e_1_2_12_25_2","first-page":"59","article-title":"Pharmacokinetics of the H1\u2010receptor antagonist ebastine and its active metabolite carebastine in healthy subjects","volume":"44","author":"Yamaguchi T","year":"1994","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127002237990"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199805000-00005"},{"issue":"10","key":"e_1_2_12_28_2","first-page":"S390","article-title":"Comparative pharmacokinetics of ebastine\/carebastine in liver cirrhosis and healthy volunteers following administration of a 10\u2003mg ebastine tablet","volume":"10","author":"Huang M\u2010Y","year":"1993","journal-title":"Pharm Res"},{"key":"e_1_2_12_29_2","first-page":"566","article-title":"N\u2010Dealkylation and hydroxylation of ebastine by human liver cytochrome P450","volume":"26","author":"Hashizume T","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.1.298"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.010488"},{"key":"e_1_2_12_32_2","unstructured":"Laboratorios AlmirallSA.Spanish Summary of product characteristics: Ebastine2004."},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443020-00004"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)83555-3"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746060-00006"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02348.x"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb04199.x"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb05694.x"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01740667"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2000.tb00423.x"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61952-7"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074308"},{"key":"e_1_2_12_43_2","first-page":"442","article-title":"Suppression of the skin reaction to histamine by ebastine","volume":"74","author":"Nelson HS","year":"1995","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2002.1s3426.x"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2001.056006553.x"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62941-9"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01969062"},{"key":"e_1_2_12_48_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199600521-00005"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199917060-00003"},{"key":"e_1_2_12_50_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2007.28.3029"},{"key":"e_1_2_12_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1989.tb01424.x"},{"key":"e_1_2_12_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259166"},{"key":"e_1_2_12_53_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199600521-00009"},{"key":"e_1_2_12_54_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199600521-00006"},{"key":"e_1_2_12_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63269-3"},{"key":"e_1_2_12_56_2","first-page":"56","article-title":"A randomized, double\u2010blind, placebo\u2010controlled study comparing the efficacy and safety of ebastine (20\u2003mg and 10\u2003mg) to loratadine 10\u2003mg once daily in the treatment of seasonal allergic rhinitis","volume":"14","author":"Hampel F","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_12_57_2","doi-asserted-by":"publisher","DOI":"10.1159\/000077357"},{"key":"e_1_2_12_58_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.105525"},{"key":"e_1_2_12_59_2","first-page":"41","article-title":"A multicentre double\u2010blind placebo controlled dose response study of ebastine in ragweed SA patients","volume":"51","author":"Grossman J","year":"1996","journal-title":"Allergy"},{"issue":"52","key":"e_1_2_12_60_2","first-page":"150","article-title":"Placebo\u2010controlled trial of ebastine 20\u2003mg and 10\u2003mg once daily vs loratadine 10\u2003mg once daily in the treatment of seasonal allergic rhinitis (SAR)","volume":"54","author":"Bernstein D","year":"1999","journal-title":"Eur J Allergy Clin Immunol"},{"key":"e_1_2_12_61_2","first-page":"199","article-title":"A double\u2010blind placebo controlled study of the efficacy and tolerability of ebastine and loratadine in seasonal allergic rhinitis patients [abstract]","volume":"50","author":"Luria X","year":"1995","journal-title":"Allergy"},{"key":"e_1_2_12_62_2","doi-asserted-by":"publisher","DOI":"10.1159\/000088869"},{"key":"e_1_2_12_63_2","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2003.25.2.723684"},{"key":"e_1_2_12_64_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.1999.00984.x"},{"key":"e_1_2_12_65_2","first-page":"615","article-title":"Ebastine in perennial allergic rhinitis","volume":"67","author":"Picado Vall\u00e9s C","year":"1991","journal-title":"Ann Allergy"},{"key":"e_1_2_12_66_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199816060-00001"},{"key":"e_1_2_12_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62991-2"},{"key":"e_1_2_12_68_2","first-page":"277","article-title":"Ebastine, traitement de la rhinite persistante chez l\u2019enfant","volume":"28","author":"Benavente V","year":"1996","journal-title":"Allerg Immunol"},{"key":"e_1_2_12_69_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639109086774"},{"key":"e_1_2_12_70_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199600521-00008"},{"key":"e_1_2_12_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01500.x"},{"key":"e_1_2_12_72_2","doi-asserted-by":"crossref","unstructured":"MagerlM SchmolkeJ SiebenhaarF ZuberbierT MetzM MaurerM.Dermographic urticaria symptoms can be safely prevented by ebastine (abstract plus poster). XX World Allergy Congress 2007 Dec 2\u20136 Bangkok.","DOI":"10.1097\/01.WOX.0000301523.34116.c8"},{"key":"e_1_2_12_73_2","volume-title":"Clinical test of ebastina plus pseudoefedrina in seasonal allergic rhinitis [abstract 75]","author":"Luria X","year":"1994"},{"key":"e_1_2_12_74_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2340\/0001555580117121","article-title":"Treatment of mosquito bites with ebastine: a field trial","volume":"80","author":"Karpinnen A","year":"2000","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_12_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2004.03.009"},{"key":"e_1_2_12_76_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1999.0290s3200.x"},{"key":"e_1_2_12_77_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01345.x"},{"key":"e_1_2_12_78_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2001.00411.x"},{"issue":"73","key":"e_1_2_12_79_2","first-page":"243","article-title":"Ebastine has no effect on QTc interval at doses up to 50 times the therapeutic dose [abstract 779]","volume":"57","author":"Gispert J","year":"2002","journal-title":"Allergy"},{"key":"e_1_2_12_80_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1999.0290s3133.x"},{"key":"e_1_2_12_81_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.01471.x"},{"key":"e_1_2_12_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb05289.x"},{"key":"e_1_2_12_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00314920"},{"key":"e_1_2_12_84_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb05894.x"},{"key":"e_1_2_12_85_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079901753403171"},{"key":"e_1_2_12_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb01140.x"},{"issue":"1","key":"e_1_2_12_87_2","first-page":"S5","article-title":"Phase I, single dose, open\u2010label, randomized, crossover bio\u2010equivalence studies of ebastine 10\u2003mg and 20\u2003mg regular tablets vs. 10 and 20\u2003mg fast\u2010dissolving tablets in healthy male volunteers","volume":"14","author":"Salv\u00e0 M","year":"2004","journal-title":"J Invest Allergol Clin Immunol"},{"key":"e_1_2_12_88_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200727070-00002"},{"key":"e_1_2_12_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.05.001"},{"key":"e_1_2_12_90_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.8.4.337"},{"key":"e_1_2_12_91_2","first-page":"13","article-title":"Preferred attributes of the new fast dissolving tablet (FDT) formulation of ebastine in patients with allergy","volume":"10","author":"Roger A","year":"2006","journal-title":"J Outcome Res"},{"key":"e_1_2_12_92_2","doi-asserted-by":"publisher","DOI":"10.1157\/13088176"},{"key":"e_1_2_12_93_2","first-page":"2","article-title":"Aceptaci\u00f3n, expectativas y satisfaci\u00f3n de la formulaci\u00f3n flas para el tratamiento de la alergia","volume":"372","author":"Roger A","year":"2007","journal-title":"Farmcologia"},{"key":"e_1_2_12_94_2","first-page":"225","article-title":"Evaluation of the patient\u2019s satisfaction with the new ebastine formulation in patients suffering from allergic rhinitis [abstract 619]","volume":"62","author":"Roger A","year":"2007","journal-title":"Allergy"},{"key":"e_1_2_12_95_2","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.1.3.381"},{"key":"e_1_2_12_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01144.x"},{"key":"e_1_2_12_97_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01620.x"},{"key":"e_1_2_12_98_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00802.x"},{"key":"e_1_2_12_99_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00805.x"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2008.01897.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2008.01897.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T20:17:09Z","timestamp":1694463429000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2008.01897.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,11]]},"references-count":98,"journal-issue":{"issue":"s89","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1398-9995.2008.01897.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2008.01897.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,11]]}}}